<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146676</url>
  </required_header>
  <id_info>
    <org_study_id>2010H0331</org_study_id>
    <nct_id>NCT03146676</nct_id>
  </id_info>
  <brief_title>The Ohio State University Dermatology Biorepository</brief_title>
  <official_title>The Ohio State University Dermatology Biorepository</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will create and extend a source of clinical specimens for the future study of&#xD;
      inflammatory skin disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A variety of molecular techniques can be used to investigate diseases by analyzing protein,&#xD;
      DNA, and RNA. Flow cytometry, Polymerase chain reaction (PCR), histology and&#xD;
      immunohistochemistry are assays which can identify specific cell populations and provide&#xD;
      valuable information regarding the pathologic characteristics of those populations. Flow&#xD;
      cytometry analyzes the surface markers of cells. Histology and immunohistochemistry further&#xD;
      characterize surface and cellular molecules and aid in the diagnosis of certain skin&#xD;
      diseases. Gene expression profiling allows investigators to examine the genes detectable to&#xD;
      determine the function of the cells involved, and PCR techniques are useful for the diagnosis&#xD;
      of certain conditions and for DNA analysis.&#xD;
&#xD;
      By procuring blood, skin tissue, and swab samples from patients with and without neoplastic&#xD;
      and inflammatory skin disorders at the time of their appointments, the hypothesize that&#xD;
      future translational research can be conducted on such specimens using the aforementioned&#xD;
      techniques to further understand disease mechanisms in cutaneous disorders, and to&#xD;
      potentially discover defective function and genetic mutations within cells from patients with&#xD;
      neoplastic and inflammatory skin disorders. By establishing a tissue bank, we aim to lay the&#xD;
      foundation for future work that will improve our understanding of the biology and natural&#xD;
      history of neoplastic and inflammatory cutaneous diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Source of clinical specimens for the future study of neoplastic and inflammatory skin disorders</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Skin Tissue, Peripheral blood mononuclear cells, skin swabs, and saliva.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any person that meets the inclusion/exclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Seen by an Ohio State University (OSU) Dermatology provider on the main University&#xD;
             Hospital campus, including the James Cancer Hospital, OSU Dermatology East, OSU&#xD;
             Dermatology at the Ohio State Eye and Ear Institute, Martha Morehouse Medical&#xD;
             Pavilion, and OSU Dermatology at Upper Arlington after the date of approval of this&#xD;
             protocol&#xD;
&#xD;
          -  Ability to provide informed consent, or parent or legal guardian capable of providing&#xD;
             consent for child or mentally handicapped individuals&#xD;
&#xD;
          -  Willingness to participate in a research study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Kaffenberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatologist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica Kaffenberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin Frey</last_name>
    <phone>614-366-2025</phone>
    <email>erin.frey@osumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shelby Snodgrass</last_name>
    <phone>614-366-9201</phone>
    <email>shelby.snodgrass@osumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OSU Dermatology West</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Frey</last_name>
      <phone>614-366-2025</phone>
      <email>erin.frey@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Kaffenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Kaffenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Ben H Kaffenberger</investigator_full_name>
    <investigator_title>Dermatologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

